Bausch + Lomb Corp

Bausch & Lomb delivered a modest beat in the second quarter of 2025, posting adjusted earnings of $0.07 per share against a consensus estimate of $0.06, a 16.67% positive surprise, while revenue climbed 5.1% year-over-year to $1.28 billion on broad-based momentum across its portfolio. The standout driver was Vision Care, which generated $753.00 million in segment revenue, up 8% as reported, propelled by a dry eye franchise that has reached roughly $1.00 billion in trailing twelve-month sales, alongside gains in Daily SiHy contact lenses and consumer brands including LUMIFY and ARTELAC. The strong top-line performance came despite an operating loss of $11.00 million, higher interest expense of $128.00 million tied partly to a debt refinancing, and lingering headwinds from the enVista IOL voluntary recall, though full production has since resumed. Management cited the underlying business strength and a favorable currency backdrop to raise full-year 2025 revenue guidance to $5.05 billion to $5.15 billion and lift adjusted EBITDA guidance to $860.00 million to $910.00 million, with an investor day scheduled for November 13 to highlight pipeline opportunities.